Search
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Categories: Purinergic P1 Receptor AgonistsClopidogrel
go.drugbank.com/drugs/DB00758ApprovedInvestigational,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalAminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTicagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigationalTicagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilin...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesTheophylline
go.drugbank.com/drugs/DB00277ApprovedInvestigationalA methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine recep...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesLosartan
go.drugbank.com/drugs/DB00678ApprovedInvestigationalLosartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associate...
Mixtures: LORZAAR PL FORTE100/12.5MGCategories: P-glycoprotein inhibitors, P-glycoprotein substratesTiclopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPeginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigationalPeginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 Enzyme InducersAldesleukin
go.drugbank.com/drugs/DB00041ApprovedInvestigationalAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 ge...
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 CYP3A Inhibitors